Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	24.35	65.81	14.31	46.33	71.14	250.73
Short-Term Investments	23.2	28.3	130.98	206.67	330.17	160.91
Cash & Short-Term Investments	47.55	94.11	145.29	253	401.31	411.64
Cash Growth	-56.94%	-35.23%	-42.57%	-36.96%	-2.51%	359.76%
Receivables	0.84	1.2	2.41	11.74	8.03	19.06
Prepaid Expenses	4.31	2.52	5.41	20.51	39.1	4.8
Other Current Assets	-	-	-	30	-	35.66
Total Current Assets	52.7	97.83	153.11	315.24	448.44	471.17
Property, Plant & Equipment	10.45	11.77	14.45	17.96	29.02	24.09
Long-Term Investments	3.09	1.61	2.78	2.01	3.91	4.89
Goodwill	-	-	-	10.51	10.51	10.51
Other Intangible Assets	-	-	-	2.13	2.63	3.15
Other Long-Term Assets	2.01	1.98	0.61	0.68	1.43	25.96
Total Assets	68.24	113.2	170.95	348.53	495.94	539.77
Accounts Payable	16.12	6.44	4.65	21.08	27.97	1.47
Accrued Expenses	1.51	13.13	18.64	26.42	30.55	30.08
Current Portion of Long-Term Debt	-	-	16.77	-	-	-
Current Portion of Leases	2.66	2.5	2.41	2.8	2.6	2.33
Current Unearned Revenue	-	-	0.11	2.56	4.62	7.58
Other Current Liabilities	11.42	13.26	-	44	-	0.25
Total Current Liabilities	31.71	35.33	42.57	96.87	65.74	41.71
Long-Term Debt	-	-	-	16.61	14.96	18.66
Long-Term Leases	8	9.37	11.03	12.66	15.46	18.06
Long-Term Unearned Revenue	-	-	-	-	0.06	0.12
Long-Term Deferred Tax Liabilities	-	-	-	0.03	0.03	0.03
Other Long-Term Liabilities	-	-	-	-	0.01	0.06
Total Liabilities	39.71	44.69	53.6	126.17	96.27	78.63
Common Stock	0.04	0.04	0.02	0.02	0.22	0.19
Additional Paid-In Capital	1,803	1,799	1,741	1,711	1,610	1,367
Retained Earnings	-1,773	-1,730	-1,623	-1,488	-1,210	-906.2
Comprehensive Income & Other	-0.66	-0.68	-0.66	-0.7	-0.28	-0.26
Total Common Equity	28.53	68.5	117.35	222.36	399.67	461.14
Shareholders' Equity	28.53	68.5	117.35	222.36	399.67	461.14
Total Liabilities & Equity	68.24	113.2	170.95	348.53	495.94	539.77
Total Debt	10.66	11.87	30.21	32.07	33.02	39.05
Net Cash (Debt)	36.89	82.25	115.08	220.92	368.29	372.59
Net Cash Growth	-62.14%	-28.53%	-47.91%	-40.01%	-1.16%	-
Net Cash Per Share	1.09	3.03	5.19	11.11	21.16	28.82
Filing Date Shares Outstanding	53.14	36.67	23.37	21.68	18.12	17.3
Total Common Shares Outstanding	53.14	36.1	22.79	21.09	18.12	15.57
Working Capital	20.99	62.5	110.54	218.37	382.7	429.46
Book Value Per Share	0.54	1.90	5.15	10.54	22.06	29.62
Tangible Book Value	28.53	68.5	117.35	209.72	386.53	447.48
Tangible Book Value Per Share	0.54	1.90	5.15	9.94	21.34	28.74
Machinery	-	8.36	9.9	13.49	20.59	12.16
Leasehold Improvements	-	11.76	15.92	15.8	15.8	15.18

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q